Cancer
Olympic cycling legend Chris Hoy, 49, has been diagnosed with incurable Stage 4 prostate cancer, with a prognosis of two to four years to live. Despite this devastating news, Hoy has remained optimistic, learning to appreciate life and find positivity in the face of adversity. Since speaking out about his
Cancer
The Bakers, a local family from Tamworth, have been facing a tough 7 months since their 11-year-old son, George, was diagnosed with a brain tumour. George has been receiving treatment at John Hunter Hospital in Newcastle, undergoing chemotherapy and radiation therapy. Despite the challenges, George remains in great spirits and
Cancer
Researchers from Uppsala University in Sweden have conducted a study to understand the protective immunity against SARS-CoV-2 in children with cancer or hematological diseases. The study, published in Frontiers in Immunology, aimed to characterize the immune response in these patients and investigate how their compromised immune systems affect their ability
Cancer
Researchers at the Barbara Ann Karmanos Cancer Institute are conducting a Phase 1 clinical trial to study the safety of metformin when combined with chemotherapy and/or immunotherapy in patients with solid tumor cancers. The trial aims to evaluate the toxicities of metformin at multiple dose levels and determine the
Cancer
Researchers at Islamic Azad University in Tehran, Iran, have conducted a study to assess the anticancer effects of Pt-Rb and Pt-AZT on HepG2 cells. The study aimed to compare the efficacy of these two compounds in inducing apoptosis and modulating gene expression. The results showed that Pt-Rb exhibited stronger anticancer
Cancer
A Monroe County woman, Brandi Leigh Bachman, has been charged with 21 felony counts of acquiring controlled substances through fraud, identity theft, and criminal use of a communication facility. Attorney General Dave Sunday announced the charges against Bachman, who allegedly obtained nearly 8,300 oxycodone pills from 19 different providers
Cancer
Researchers at Teclison Inc. have made a significant breakthrough in cancer treatment with a new patent that discloses a method of enhancing an immune response against solid tumors. The method combines the use of hypoxia-activated bioreductive agents (HABAs) with immune checkpoint inhibitors to stimulate the immune system to attack cancer
Cancer
The HER2+ gastric cancer market is expected to experience significant growth, driven by a rising incidence of the disease, improved diagnostic protocols, and expanding therapeutic options. Recently, the FDA has approved several therapies, including ENHERTU, OPDIVO, trastuzumab, KEYTRUDA, and AIDIXI, which are further fueling the market growth. Additionally, late-stage clinical
Cancer
Researchers at Fudan University in Shanghai, China, have discovered a potential new therapeutic agent in the fight against gastric cancer. The compound, known as ginsenoside Rh7, has shown remarkable efficacy in suppressing the growth and spread of cancer cells. According to a study published in the International Journal of Medical
Cancer
Photodynamic therapy (PDT) has emerged as a novel and effective treatment approach for various types of cancers, including skin, esophagus, lung, and cervical cancers. This treatment modality uses a combination of photosensitizing drugs, light of a specific wavelength, and tissue-bound oxygen to produce cytotoxic reactive oxygen species that selectively destroy
Cancer
A study published in the journal Digestive Diseases has found that both Helicobacter pylori infection and positive family history of gastric cancer (FHx) significantly increase the risk of developing significant gastric precancerous conditions (SGPCs) in the stomach. The researchers conducted a cross-sectional study among 761 treatment-naïve adult patients with upper
Cancer
Immunophotonics, a clinical-stage biotech company, has announced the completion of the INJECTABL-1 multicenter Phase 1b/2a clinical trial of its proprietary glycan polymer, IP-001, for advanced solid tumors. The trial, conducted in five countries, aimed to evaluate the systemic immune-mediated anti-cancer effects of IP-001 following tumor ablation. The company reports
